標的タンパク質分解の世界市場：市場規模・シェア・動向分析 (種類別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

標的タンパク質分解の市場動向：

世界の標的タンパク質分解の市場規模は2024年に5億4,440万米ドルと推定され、2025年から2030年にかけてCAGR 20.80%で成長すると予測されています。

がんや神経変性疾患などの慢性疾患の頻度が絶えず増加していることに加え、ライフスタイルの変化やヘルスケア支出の増加が市場成長を加速させています。これらの疾患の高い有病率は、新規治療オプションに対する強い需要を生み出し、市場成長を促進しています。

例えば、世界保健機関 (WHO) のデータによると、2022年には約2,000万人が新たにがんと診断され、がん関連死は970万人に上った。また、診断を受けてから5年以内にがんと共に生きる人は5,350万人に上ると推定されています。

この分野における研究開発活動の拡大は、大きな市場成長機会をもたらしています。例えば、2023年12月、オーストリア科学基金 (FWF) は、標的タンパク質分解における特別研究プログラム (SFB) を、さらに4年間の2回目の助成期間として承認しました。標的タンパク質分解特別研究プログラム (SFB) は、特定のタンパク質を細胞分解の標的にする方法の理解と開発に焦点を当てた研究イニシアチブです。このプログラムは、創薬や治療介入への応用の可能性から近年大きな注目を集めている標的タンパク質分解の分野を発展させることを目的としています。

特にFDAやEMAといった機関による合理化された承認プロセスといった支援的な規制環境は、TPDに基づく治療法の採用を加速させる上で重要な役割を果たしています。基盤技術の急速な進歩が、標的タンパク質分解産業を牽引しています。タンパク質分解標的キメラ (PROTAC)、分子接着剤、リソソーム標的キメラ (LYTACs) などの革新的なアプローチの開発により、病気の原因となるタンパク質を選択的に除去するTPDの能力が拡大しました。これらの技術的ブレークスルーは、以前は治療不可能であったタンパク質を標的とする新たな道を開き、標的タンパク質分解産業の成長を牽引しています。

以前は治療不可能であったターゲットに対処する標的タンパク質分解の治療的可能性が認識されつつあることが、標的タンパク質分解産業の主要な推進力となっています。従来のアプローチでは、調節が困難なタンパク質に苦戦することが多かったが、PROTAC (タンパク質分解標的キメラ) のような技術は、病気の原因となるタンパク質の分解を促進することで、有利な解決策を提供します。この方法は、がんや神経変性疾患などの治療において大きな可能性を示しており、この分野への研究と投資が急増しています。米国国立衛生研究所 (National Institute of Health) は、PROTACsを最近の医薬品開発技術の代表的なものとして取り上げています。前臨床試験や初期段階の臨床試験での成功が増加していることから、製薬会社やバイオテクノロジー企業は、治療戦略を一変させる可能性を認識し、標的タンパク質分解をパイプラインに組み込もうとしています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 標的タンパク質分解市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 標的タンパク質分解市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 標的タンパク質分解市場：種類別の推定・動向分析

• セグメントダッシュボード
• 標的タンパク質分解市場：種類別の変動分析
• 標的タンパク質分解市場：市場規模の予測と動向分析、種類別 (2018～2030年)
• PROTAC
• 分子接着剤
• LYTAC
• その他

第5章 標的タンパク質分解市場：用途別の推定・動向分析

• セグメントダッシュボード
• 標的タンパク質分解市場：用途別の変動分析
• 標的タンパク質分解市場：市場規模の予測と動向分析、用途別 (2018～2030年)
• 創薬
• 治療法の開発
  • がん
  • 神経学
  • 感染症
  • 心血管疾患
  • その他

第6章 標的タンパク質分解市場：最終用途別の推定・動向分析

• セグメントダッシュボード
• 標的タンパク質分解市場：最終用途別の変動分析
• 標的タンパク質分解市場：市場規模の予測と動向分析、最終用途別 (2018～2030年)
• 製薬・バイオテクノロジー企業
• 学術研究機関
• 病院・臨床検査室

第7章 標的タンパク質分解市場：地域別の推定・動向分析

• 市場シェア：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業市況分析 (2024年)
• 企業プロファイル/上場企業
  • Bayer AG
  • Bio-Techne
  • BOC Sciences
  • BPS Bioscience, Inc.
  • BroadPharm
  • LifeSensors Inc.
  • MedChemExpress.
  • Merck KGaA
  • Promega Corporation
  • Thermo Fisher Scientific, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 Global Targeted protein degradation market, by region, 2018 - 2030 (USD Million)
• Table 3 Global Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 4 Global Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 5 Global Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 6 North America Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
• Table 7 North America Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 8 North America Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 9 North America Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 10 U.S. Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 11 U.S. Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 12 U.S. Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 13 Canada Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 14 Canada Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 15 Canada Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 16 Mexico Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 17 Mexico Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 18 Mexico Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 19 Europe Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
• Table 20 Europe Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 21 Europe Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 22 Europe Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 23 Germany Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 24 Germany Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 25 Germany Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 26 UK Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 27 UK Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 28 UK Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 29 France Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 30 France Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 31 France Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 32 Italy Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 33 Italy Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 34 Italy Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 35 Spain Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 36 Spain Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 37 Spain Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 38 Denmark Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 39 Denmark Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 40 Denmark Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 41 Sweden Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 42 Sweden Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 43 Sweden Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 44 Norway Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 45 Norway Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 46 Norway Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 51 China Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 52 China Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 53 China Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 54 Japan Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 55 Japan Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 56 Japan Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 57 India Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 58 India Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 59 India Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 60 South Korea Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 61 South Korea Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 62 South Korea Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 63 Australia Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 64 Australia Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 65 Australia Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 66 Thailand Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 67 Thailand Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 68 Thailand Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 69 Latin America Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
• Table 70 Latin America Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 71 Latin America Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 72 Latin America Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 73 Brazil Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 74 Brazil Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 75 Brazil Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 76 Argentina Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 77 Argentina Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 78 Argentina Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 79 MEA Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
• Table 80 MEA Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 81 MEA Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 82 MEA Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 83 South Africa Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 84 South Africa Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 85 South Africa Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 89 UAE Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 90 UAE Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 91 UAE Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
• Table 92 Kuwait Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
• Table 93 Kuwait Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
• Table 94 Kuwait Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market formulation & validation
• Fig. 4 Targeted Protein Degradation market: Market outlook
• Fig. 5 Targeted Protein Degradation market: Segment outlook
• Fig. 6 Targeted Protein Degradation market: Competitive landscape outlook
• Fig. 7 Parent market outlook
• Fig. 8 Targeted Protein Degradation market driver impact
• Fig. 9 Targeted Protein Degradation market restraint impact
• Fig. 10 Targeted Protein Degradation market: Type outlook and key takeaways
• Fig. 11 Targeted Protein Degradation market: Type movement analysis
• Fig. 12 PROTAC market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 13 Molecular Glues market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 14 LYTACs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Targeted Protein Degradation market: Application outlook and key takeaways
• Fig. 17 Targeted Protein Degradation market: Application movement analysis
• Fig. 18 Drug Discovery market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Therapy Development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Infectious Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Cardiovascular Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Targeted Protein Degradation market: End Use outlook and key takeaways
• Fig. 26 Targeted Protein Degradation market: End Use movement analysis
• Fig. 27 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 28 Academic & Research Institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Hospitals & Clinical Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Global Targeted Protein Degradation market: Regional outlook and key takeaways
• Fig. 32 Global Targeted Protein Degradation market: Regional movement analysis
• Fig. 33 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Key country dynamics
• Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Target Disease Prevalence
• Fig. 37 Key country dynamics
• Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Target Disease Prevalence
• Fig. 40 Key country dynamics
• Fig. 41 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Target Disease Prevalence
• Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Key country dynamics
• Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Target Disease Prevalence
• Fig. 47 Key country dynamics
• Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Target Disease Prevalence
• Fig. 50 Key country dynamics
• Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Target Disease Prevalence
• Fig. 53 Key country dynamics
• Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Target Disease Prevalence
• Fig. 56 Key country dynamics
• Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Target Disease Prevalence
• Fig. 59 Key country dynamics
• Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Target Disease Prevalence
• Fig. 62 Key country dynamics
• Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Target Disease Prevalence
• Fig. 65 Key country dynamics
• Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Target Disease Prevalence
• Fig. 68 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Target Disease Prevalence
• Fig. 72 Key country dynamics
• Fig. 73 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Target Disease Prevalence
• Fig. 75 Key country dynamics
• Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Target Disease Prevalence
• Fig. 78 Key country dynamics
• Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Target Disease Prevalence
• Fig. 81 Key country dynamics
• Fig. 82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Target Disease Prevalence
• Fig. 84 Key country dynamics
• Fig. 85 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Target Disease Prevalence
• Fig. 87 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Target Disease Prevalence
• Fig. 91 Key country dynamics
• Fig. 92 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Target Disease Prevalence
• Fig. 94 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Target Disease Prevalence
• Fig. 98 Key country dynamics
• Fig. 99 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Target Disease Prevalence
• Fig. 101 Key country dynamics
• Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Target Disease Prevalence
• Fig. 104 Key country dynamics
• Fig. 105 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Target Disease Prevalence

Targeted Protein Degradation Market Trends:

The global targeted protein degradation market size was estimated at USD 544.4 million in 2024 and is projected to grow at a CAGR of 20.80% from 2025 to 2030. The constantly growing frequency of chronic disease conditions such as cancer and neurodegenerative diseases, along with changing lifestyles and increasing healthcare spending, are accelerating the market growth. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth.

For instance, data from the World Health Organization (WHO) indicates that in 2022, around 20 million individuals were newly diagnosed with cancer, and there were 9.7 million cancer-related deaths. It's estimated that 53.5 million people were living with cancer within five years after receiving their diagnosis.

The expanding number of research and development activities in this field provides significant market growth opportunities. For instance, in December 2023, the Austrian Science Fund (FWF) approved the Special Research Program (SFB) in Targeted Protein Degradation for a second funding period of another four years. The SFB in Targeted protein degradation is a research initiative focusing on understanding and developing methods to target specific proteins for cell degradation. This program aims to advance the field of targeted protein degradation, which has gained significant attention in recent years due to its potential applications in drug discovery and therapeutic interventions.

The supportive regulatory environment, particularly the streamlined approval processes by agencies such as the FDA and EMA, has played a crucial role in accelerating the adoption of TPD-based therapies. Rapid advancements in the underlying technologies drive the targeted protein degradation industry. The development of innovative approaches, such as proteolysis-targeting chimeras (PROTACs), molecular glues, and lysosome-targeting chimeras (LYTACs), has expanded TPD's capabilities to eliminate disease-causing proteins selectively. These technological breakthroughs have opened up new avenues for targeting previously undruggable proteins, driving the growth of the targeted protein degradation industry.

The increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets is a key driver for the targeted protein degradation industry. Traditional approaches often struggle with proteins that are difficult to modulate, but technologies such as PROTACs (proteolysis-targeting chimeras) provide a favorable solution by promoting the degradation of disease-causing proteins. This method has shown considerable promise in treating conditions such as cancer and neurodegenerative disorders, sparking a surge in research and investment in this area. The National Institute of Health highlights PROTACs as a leading drug development technology in recent years. The increasing success in preclinical and early-phase clinical trials drives pharmaceutical and biotech companies to integrate targeted protein degradation into their pipelines, recognizing its potential to transform therapeutic strategies.

Global Targeted Protein Degradation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global targeted protein degradation market report based on type, application, end-use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• PROTAC
• Molecular Glues
• LYTACs
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Drug Discovery
• Therapy Development
  • Cancer
  • Neurology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Clinical Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Targeted Protein Degradation Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing frequency of chronic diseases
    • 3.2.1.2. Research and development activities
    • 3.2.1.3. Increasing recognition of the therapeutic potential of targeted protein degradation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost
    • 3.2.2.2. Stringent regulations associated with approvals for novel TPD based therapies
• 3.3. Targeted Protein Degradation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Targeted Protein Degradation Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Targeted Protein Degradation Market Type Movement Analysis
• 4.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. PROTAC
  • 4.4.1. PROTAC market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Molecular Glues
  • 4.5.1. Molecular Glues market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. LYTACs
  • 4.6.1. LYTACs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Targeted Protein Degradation Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Targeted Protein Degradation Market Application Movement Analysis
• 5.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Discovery
  • 5.4.1. Drug Discovery market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Therapy Development
  • 5.5.1. Therapy Development market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Cancer
    • 5.5.2.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Neurology
    • 5.5.3.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Infectious Diseases
    • 5.5.4.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Cardiovascular Diseases
    • 5.5.5.1. Cardiovascular Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Others
    • 5.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Targeted Protein Degradation Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Targeted Protein Degradation Market End Use Movement Analysis
• 6.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospitals & Clinical Laboratories
  • 6.6.1. Hospitals & Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Targeted Protein Degradation Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Target disease prevalence
    • 7.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Target disease prevalence
    • 7.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Target disease prevalence
    • 7.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Target disease prevalence
    • 7.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Target disease prevalence
    • 7.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Target disease prevalence
    • 7.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Target disease prevalence
    • 7.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Target disease prevalence
    • 7.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Target disease prevalence
    • 7.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Target disease prevalence
    • 7.6.7.4. Regulatory framework
    • 7.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Target disease prevalence
    • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Target disease prevalence
    • 7.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Target disease prevalence
    • 7.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Bayer AG
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Type benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Bio-Techne
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Type benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. BOC Sciences
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Type benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. BPS Bioscience, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. BroadPharm
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. LifeSensors Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. MedChemExpress.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Merck KGaA
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Promega Corporation
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Thermo Fisher Scientific, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Type benchmarking
    • 8.4.10.4. Strategic initiatives